These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 33844469)

  • 1. Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial.
    Levy AS; Krailo M; Chi S; Villaluna D; Springer L; Williams-Hughes C; Fouladi M; Gajjar A
    Pediatr Blood Cancer; 2021 Aug; 68(8):e29031. PubMed ID: 33844469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience.
    Aguilera D; Mazewski C; Fangusaro J; MacDonald TJ; McNall-Knapp RY; Hayes LL; Kim S; Castellino RC
    Childs Nerv Syst; 2013 Apr; 29(4):589-96. PubMed ID: 23296323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Analysis of a Three-Drug Regimen Containing Bevacizumab for the Treatment of Recurrent Pediatric
    Chen Z; Tian F; Chen X
    Front Public Health; 2022; 10():914536. PubMed ID: 35719637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab-containing regimen in relapsed/progressed brain tumors: a single-institution experience.
    Schiavetti A; Varrasso G; Mollace MG; Dominici C; Ferrara E; Papoff P; Di Biasi C
    Childs Nerv Syst; 2019 Jun; 35(6):1007-1012. PubMed ID: 30903281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study.
    Le Teuff G; Castaneda-Heredia A; Dufour C; Jaspan T; Calmon R; Devos A; McHugh K; Leblond P; Frappaz D; Aerts I; Zwaan CM; Ducassou S; Chastagner P; Verschuur A; Corradini N; Casanova M; Rubie H; Riccardi R; Le Deley MC; Vassal G; Geoerger B;
    Pediatr Blood Cancer; 2020 Jan; 67(1):e28032. PubMed ID: 31595663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†.
    Chauffert B; Feuvret L; Bonnetain F; Taillandier L; Frappaz D; Taillia H; Schott R; Honnorat J; Fabbro M; Tennevet I; Ghiringhelli F; Guillamo JS; Durando X; Castera D; Frenay M; Campello C; Dalban C; Skrzypski J; Chinot O
    Ann Oncol; 2014 Jul; 25(7):1442-1447. PubMed ID: 24723487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial.
    Cefalo G; Massimino M; Ruggiero A; Barone G; Ridola V; Spreafico F; Potepan P; Abate ME; Mascarin M; Garrè ML; Perilongo G; Madon E; Colosimo C; Riccardi R
    Neuro Oncol; 2014 May; 16(5):748-53. PubMed ID: 24482446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab.
    Lu G; Zhu P; Rao M; Linendoll N; Buja LM; Bhattacharjee MB; Brown RE; Ballester LY; Tian X; Pilichowska M; Wu JK; Hergenroeder GW; Glass WF; Chen L; Zhang R; Pillai AK; Hunter RL; Zhu JJ
    J Neurooncol; 2022 Oct; 160(1):221-231. PubMed ID: 36203027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study.
    Modak S; Kushner BH; Basu E; Roberts SS; Cheung NK
    Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28111925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma.
    Gilbert MR; Pugh SL; Aldape K; Sorensen AG; Mikkelsen T; Penas-Prado M; Bokstein F; Kwok Y; Lee RJ; Mehta M
    J Neurooncol; 2017 Jan; 131(1):193-199. PubMed ID: 27770279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of irinotecan and temozolomide with bevacizumab in children with recurrent/refractory central nervous system tumors.
    Metts J; Harrington B; Salman E; Bradfield SM; Flanary J; Mosha M; Amankwah E; Stapleton S
    Childs Nerv Syst; 2022 May; 38(5):919-928. PubMed ID: 35260913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.
    Peters KB; Lipp ES; Miller E; Herndon JE; McSherry F; Desjardins A; Reardon DA; Friedman HS
    J Neurooncol; 2018 Apr; 137(2):349-356. PubMed ID: 29264836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.
    Balana C; De Las Penas R; Sepúlveda JM; Gil-Gil MJ; Luque R; Gallego O; Carrato C; Sanz C; Reynes G; Herrero A; Ramirez JL; Pérez-Segura P; Berrocal A; Vieitez JM; Garcia A; Vazquez-Estevez S; Peralta S; Fernandez I; Henriquez I; Martinez-Garcia M; De la Cruz JJ; Capellades J; Giner P; Villà S
    J Neurooncol; 2016 May; 127(3):569-79. PubMed ID: 26847813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irinotecan, vincristine, cisplatin, cyclophosphamide, and etoposide for refractory or relapsed medulloblastoma/PNET in pediatric patients.
    Kim H; Kang HJ; Lee JW; Park JD; Park KD; Shin HY; Ahn HS
    Childs Nerv Syst; 2013 Oct; 29(10):1851-8. PubMed ID: 23748464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial.
    Defachelles AS; Bogart E; Casanova M; Merks JHM; Bisogno G; Calareso G; Gallego Melcon S; Gatz SA; Le Deley MC; McHugh K; Probst A; Rocourt N; van Rijn RR; Wheatley K; Minard-Colin V; Chisholm JC
    J Clin Oncol; 2021 Sep; 39(27):2979-2990. PubMed ID: 34343032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Notable response of a young adult with recurrent glioblastoma multiforme to vincristine-irinotecan-temozolomide and bevacizumab.
    Papageorgiou GI; Tsakatikas SA; Fioretzaki RG; Kosmas C
    Anticancer Drugs; 2021 Mar; 32(3):330-336. PubMed ID: 33229903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab Alone Versus Bevacizumab Plus Irinotecan in Patients With Recurrent Glioblastoma: A Nationwide Population-Based Study.
    Lee Y; Lee E; Roh TH; Kim SH
    J Korean Med Sci; 2024 Sep; 39(34):e244. PubMed ID: 39228184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
    Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
    Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial.
    Moreno L; Weston R; Owens C; Valteau-Couanet D; Gambart M; Castel V; Zwaan CM; Nysom K; Gerber N; Castellano A; Laureys G; Ladenstein R; Rössler J; Makin G; Murphy D; Morland B; Vaidya S; Thebaud E; van Eijkelenburg N; Tweddle DA; Barone G; Tandonnet J; Corradini N; Chastagner P; Paillard C; Bautista FJ; Gallego Melcon S; De Wilde B; Marshall L; Gray J; Burchill SA; Schleiermacher G; Chesler L; Peet A; Leach MO; McHugh K; Hayes R; Jerome N; Caron H; Laidler J; Fenwick N; Holt G; Moroz V; Kearns P; Gates S; Pearson ADJ; Wheatley K;
    J Clin Oncol; 2024 Apr; 42(10):1135-1145. PubMed ID: 38190578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of vincristine, irinotecan, temozolomide and bevacizumab (vitb) in pediatric patients with relapsed solid tumors.
    Venkatramani R; Malogolowkin M; Davidson TB; May W; Sposto R; Mascarenhas L
    PLoS One; 2013; 8(7):e68416. PubMed ID: 23894304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.